Quarterly data.
GUILFORD PHARMACEUTICALS INC.
AND SUBSIDIARIES
Financial Highlights
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
Three Months Ended Year Ended
December 31, December 31,
(Unaudited) (Unaudited) (Audited)
1999 1998 1999 1998
Revenues:
Contract revenues $5,000 -- $9,500 $1,000
Product sales 939 1,285 4,371 3,860
License and royalty
revenues 642 686 2,427 2,713
Revenues under
collaborative
agreements 1,581 1,389 5,263 4,910
Total revenues 8,162 3,360 21,561 12,483
Costs and expenses:
Cost of sales 562 769 2,308 2,036
Research and
development 11,262 10, 278 41,922 37,722
General and
administrative 2,898 2,822 11,281 10,546
Total costs and
expenses 14,722 13,869 55,511 50,304
Loss from operations (6,560) (10,509) (33,950) (37,821)
Interest and other
income, net 2,012 1,879 7,082 8,123
Net loss $(4,548) $(8,630) $(26,868) $ (29,698)
Loss per share:
Basic and diluted
loss per share $ (.20) $(.44) $(1.31) $(1.52)
Shares used in
calculation of:
Basic and diluted
loss per share 23,049 19,555 20,475 19,479
Condensed Consolidated Balance Sheets
(In thousands)
December 31, December 31,
1999 1998
(Unaudited) (Audited)
Assets
Cash, cash equivalents
and investments $144,718 $128,261
Plant and equipment, net 15,793 18,790
Inventories 1,348 1,291
Other assets 2,383 2,617
Total assets $164,242 $150,959
Liabilities and
Stockholders' Equity
Current liabilities $12,110 $11,814
Long-term debt, net of
current portion 7,152 8,766
Stockholders' equity 144,980 130,379
Total liabilities
and stockholders'
equity $164,242 $150,959
Internet address: guilfordpharm.com |
